Compare MTD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTD | BIIB |
|---|---|---|
| Founded | 1991 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8B | 24.2B |
| IPO Year | 1997 | 1991 |
| Metric | MTD | BIIB |
|---|---|---|
| Price | $1,431.49 | $173.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 23 |
| Target Price | ★ $1,423.33 | $179.48 |
| AVG Volume (30 Days) | 119.8K | ★ 1.5M |
| Earning Date | 02-05-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.22 | N/A |
| EPS | ★ 40.11 | 10.97 |
| Revenue | $3,941,791,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $4.30 | $3.56 |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $35.55 | ★ $15.77 |
| Revenue Growth | ★ 4.77 | 4.77 |
| 52 Week Low | $946.69 | $110.04 |
| 52 Week High | $1,525.17 | $190.20 |
| Indicator | MTD | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 48.70 |
| Support Level | $1,392.16 | $170.04 |
| Resistance Level | $1,456.75 | $175.29 |
| Average True Range (ATR) | 37.48 | 5.47 |
| MACD | -6.54 | -0.69 |
| Stochastic Oscillator | 30.83 | 43.41 |
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 28%, China about 16% and the rest of the world about 19%.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).